Diabetes
Conditions
Keywords
Type 2 diabetic volunteers
Brief summary
Preclinical studies have demonstrated in mouse models that (PYR1)-apelin-13 exerts a glucose-regulating action in vivo. The (PYR1)-apelin-13 effect on insulin sensitivity in healthy overweighed volunteers has been previously assessed in a phase I clinical trial (APELINS study; NCT02033473). The APELINS-2 clinical trial aims to expand the initial proof of concept to the population targeted by future innovative insulin-sensitizing therapies: patients living with type 2 diabetes.
Detailed description
Insulin sensitivity is measured using the hyperinsulinemic euglycemic glucose clamp method. The hypothesis of the investigators is that a continuous (pyr1)-apelin-13 infusion improves insulin sensitivity of type 2 diabetic patients compared to placebo infusion. This study could bring new elements for understanding the pathophysiology of insulin resistance and type 2 diabetes mellitus in humans and could lead to the development of innovative therapies in type 2 diabetes mellitus.
Interventions
DRUGapelin
Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
DRUGplacebo
2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
Sponsors
Société Francophone du Diabète
University Hospital, Toulouse
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of type2 diabetes * Body Mass Index between 27 and 33 kg / cm ² * HbA1c \< 8.5% * Non-pathological Electrocardiogram * Heart rate between 50 and 80 beats per minute at rest. * Complete Blood Count (CBC) with no significant anomaly in terms of the investigator.. * Serum electrolytes without clinically significant abnormalities in terms of the investigator. * Liver function tests without clinically significant abnormalities in terms of the investigator * Renal function tests without clinically significant abnormalities in terms of the investigator * Good peripheral vein (forearm and back of the hand). * Agreement to participate in the establishment of a serum bank. * Ability to sign informed consent. * Affiliation to a social security scheme
Exclusion criteria
* Secondary prevention of cardio-vascular disease * Insulin therapy or Glucagon Like Peptid 1 (GLP-1) analogs therapy in the 6 months before inclusion. * Risk factor, treatment or electrocardiogram as recommended by International Conference on Harmonization (ICH) E14 Clinical Evaluation of QT / QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs * Repeated a QTc interval\> 450 ms measurement * Risk factor for torsade de pointes: myocardial infarction, hypokalemia, family history of long QT syndrome * Personal history of cancer. * Positive HIV serology. * Hepatitis B serology positive. * Positive hepatitis C serology. * Cognitive impairment or mental illness (at the discretion of the investigator). * Chronic excessive alcohol consumption (consumption \> 30g/day or 210g/week). * Person under judicial protection, guardianship. * Subject with a resting systolic blood pressure greater than 140 mm Hg and diastolic blood pressure greater than 90 mmHg * Smoking more than 10 cigaret per day and can not be interrupted for 24 hours.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Delta between Glucose Infusion Rate | 240 minutes | Difference between glucose infusion rate measured during investigational product infusion (mean of values measured at 210, 215, 220, 225, 230, 235 and 240 minutes) and basal glucose infusion rate (mean of values measured at 90, 95, 100, 105, 110, 115 and 120 minutes). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| systolic blood pressure and diastolic blood pressure | 240 minutes | — |
| heart rate | 240 minutes | — |
| Measure of QTc interval with electrocardiogram examination | 240 minutes | — |
| Measure of M-value (a glucose physiological parameter) | 240 minutes | Difference between value of product time (mean of values measured at 210, 215, 220, 225, 230, 235 and 240 minutes) and value of basal (mean of values measured at 90, 95, 100, 105, 110, 115 and 120 minutes). |
| Dosage of plasma proteins | 240 minutes | A kinetic is realized with samples at 0, 15, 30, 45, 60, 75, 90, 100, 110, 120, 135, 150, 165, 180, 195, 200, 220, 230 and 240 minutes |
| Clinic sign of apelin allergy | 240 minutes | Modification in physiological parameters |
| Clinic sign of apelin toxicity | 240 minutes | Modification in physiological parameters |
| Clinic sign of apelin intolerance | 240 minutes | — |
Countries
France
Outcome results
None listed